Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Ipratropium bromide
Boehringer Ingelheim Limited
R03BB; R03BB01
Ipratropium bromide
250 microgram(s)/millilitre
Nebuliser solution
Product subject to prescription which may be renewed (B)
Anticholinergics; ipratropium bromide
Marketed
1996-06-10
PACKAGE LEAFLET: INFORMATION FOR THE USER READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets troublesome or serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What ATROVENT 250 UDVs, 1 ml are and what they are used for 2. Before you use ATROVENT 250 UDVs, 1ml 3. How to use ATROVENT 250 UDVs, 1 ml 4. Possible side effects 5. How to store ATROVENT 250 UDVs, 1 ml 6. Further information 1. WHAT ATROVENT 250 UDVS, 1 ML ARE AND WHAT THEY ARE USED FOR The name of your medicine is ATROVENT 250 UDVs, 250 micrograms/1 ml Nebuliser Solution (called ATROVENT in the rest of this leaflet). You use it with a device called a ‘nebuliser’. This changes your medicine into a mist for you to breathe in. ATROVENT contains a medicine called ipratropium bromide. This belongs to a group of medicines called bronchodilators. It is used to make breathing easier for people who have breathing difficulties, such as in chronic asthma or chronic obstructive pulmonary disease (COPD). ATROVENT can be taken at the same time as medicines called ‘beta 2 -agonist bronchodilators’ such as salbutamol. ATROVENT works by opening up your airways. 2. BEFORE YOU USE ATROVENT 250 UDVS, 1 ML DO NOT USE ATROVENT IF: • You are allergic (hypersensitive) to ipratropium bromide or any of the other ingredients in ATROVENT (listed in Section 6 below) • You are allergic (hypersensitive) to medicines that are similar to ATROVENT, such as atropine Do not use this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before using ATROVENT. TAKE SPECIAL CARE WITH ATROVENT Check with your doctor or pharmacist before using you Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atrovent 250 UDVs 250 micrograms/ 1ml Nebuliser Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each single dose unit contains 250 micrograms ipratropium bromide (as ipratropium bromide monohydrate) in 1 ml of solution (0.025% w/v) For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Nebuliser Solution (nebuliser liquid) A clear, colourless aqueous solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Atrovent 250 UDVs, 1ml are indicated for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease and, when used concomitantly with inhaled beta 2 -agonists, for treatment of acute and chronic asthma and acute bronchospasm associated with chronic obstructive pulmonary disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage should be adapted to the individual needs of the patient. The following doses are recommended: Adults (including the elderly) and adolescents > 12 years of age: 500 micrograms 3 to 4 times daily. For treatment of acute bronchospasm, 500 micrograms. Repeated doses can be administered until the patient is stable. The time interval between the doses may be determined by the physician. It is advisable not to exceed the recommended daily dose during either acute or maintenance treatment. Daily doses exceeding 2 mg in adults and adolescents > 12 years of age should only be given under medical supervision. Children < 12 years of age: 250 micrograms up to a total daily dose of 1mg. The time interval between doses may be determined by the physician. For acute bronchospasm, repeated doses may be administered until the patient is stable. The time interval between doses may be determined by the physician. It is advisable not to exceed the recommended daily dose. Daily doses exceeding 1mg in this age group should be given under medical supervision. There is limited information for children < 6 years of age, therefore the recommended dose should only be given under medical supe Read the complete document